Skye Bioscience, Inc.
DE ˙ DB ˙ US83086J1016
0,65 € ↑0,06 (9,24%)
2026-06-04
CENA AKCJI
SecurityDE:09R / Skye Bioscience, Inc.
InstitutionUBS Group AG
Latest Disclosed Ownership45,762 shares
Latest Disclosed Value $ 28,143
UBS Group AG reports 244.44% increase in ownership of 09R / Skye Bioscience, Inc.

On May 5, 2026 - UBS Group AG filed a 13F-HR form disclosing ownership of 45,762 shares of Skye Bioscience, Inc. (DE:09R) valued at $21,325 USD as of March 31, 2026. The entity filed a previous 13F-HR on January 29, 2026 disclosing 13,286 shares of Skye Bioscience, Inc.. This represents a change in shares of 244.44% during the quarter. The current value of the position is $29,745 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-05 2026-03-31 13F SKYE BIOSCIENCE COM NEW 83086J200 45,762 32,476 244.44 28 211.11 0.0000
2026-01-29 2025-12-31 13F SKYE BIOSCIENCE COM NEW 83086J200 13,286 -16,704 -55.70 10 -92.31 0.0000
2025-11-13 2025-09-30 13F SKYE BIOSCIENCE COM NEW 83086J200 29,990 -11,533 -27.77 118 -32.37 0.0000
2025-08-14 2025-06-30 13F SKYE BIOSCIENCE COM NEW 83086J200 41,523 -110,065 -72.61 174 -28.22 0.0000
2025-05-13 2025-03-31 13F SKYE BIOSCIENCE COM NEW 83086J200 151,588 92,012 154.44 241 43.45 0.0000
2025-02-14 2024-12-31 13F SKYE BIOSCIENCE COM NEW 83086J200 59,576 33,619 129.52 169 66.34 0.0000
2024-11-14 2024-09-30 13F SKYE BIOSCIENCE COM NEW 83086J200 25,957 20,707 394.42 101 140.48 0.0000
2024-08-14 2024-06-30 13F SKYE BIOSCIENCE COM NEW 83086J200 5,250 5,250 42 0.0000
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.